Ideas

Milk-derived protein functions as a longevity promoter: Lactoferrin, derived from milk-derived products, slows down cardiac aging, and increases lifespan, via up-regulation of BubR1 and others genes, 21/March/2019, 8.35 am
Milk-derived protein functions as a longevity promoter: Lactoferrin, derived from milk-derived products, slows down cardiac aging, and increases lifespan, via up-regulation of BubR1 and others genes, 21/March/2019, 8.35 am 1280 720 Dr Boomi's Genom-2-Discovery Center

 What they say: Introduction:  A recent study from the Department of Genetics, Paul F. Glenn Laboratories for the Biological Mechanisms of Aging Harvard Medical School, Boston, USA; and Department of Pharmacology,…

read more

Hydrogen gas-based regenerative stem cell therapy  for Myocardial Infarction:  Subcutaneous  injection of hydrogen  gas  inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction, via up-regulation of its target gene, 21/March/2019, 12.06 am
Hydrogen gas-based regenerative stem cell therapy  for Myocardial Infarction:  Subcutaneous  injection of hydrogen  gas  inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction, via up-regulation of its target gene, 21/March/2019, 12.06 am 960 720 Dr Boomi's Genom-2-Discovery Center

What they say:  A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published, in the 7 March  2013 issue of of the journal Nature,  by Prof Dimmler,…

read more

Ethyl pyruvate (EP)-based therapy for TIIDM and obesity-associated metabolic deficits: Ethyl pyruvate (EP) increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM, via down-regulation of its target gene, 20/March/2018, 12.31 pm
Ethyl pyruvate (EP)-based therapy for TIIDM and obesity-associated metabolic deficits: Ethyl pyruvate (EP) increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM, via down-regulation of its target gene, 20/March/2018, 12.31 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Department of Physiology-Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, New York, USA shows that “MC4R-dependent suppression of appetite by…

read more

Ribonucleic acid-based therapy for autoimmune diabetes: LncRNA MAR1 increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 20/March/2019, 12.16 pm
Ribonucleic acid-based therapy for autoimmune diabetes: LncRNA MAR1 increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 20/March/2019, 12.16 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, “L. Sacco” Department of Biomedical and Clinical Sciences, University of Milan, Milan…

read more

Ribonucleic acid-based therapy for glaucoma:  LncRNA UCA1 increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma,  via down regulation of its target gene, 19/March/2019, 1.51 pm
Ribonucleic acid-based therapy for glaucoma:  LncRNA UCA1 increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma,  via down regulation of its target gene, 19/March/2019, 1.51 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the The Jackson Laboratory, Bar Harbor, ME 04609, USA; Department of Ophthalmology, Tufts University of Medicine, Boston, MA 02111, USA; The Howard Hughes…

read more

Ribonucleic acid-based therapy for Diabetes Mellitus: LncRNA AFAP1-AS-1 augments the expression of FGF19 and FGF1,  attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIDM, via upregulation of its target gene, 19/March/2019, 1.45 pm
Ribonucleic acid-based therapy for Diabetes Mellitus: LncRNA AFAP1-AS-1 augments the expression of FGF19 and FGF1,  attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIDM, via upregulation of its target gene, 19/March/2019, 1.45 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say  A study from Diabetes and Obesity Center of Excellence, Department of Medicine, University of Washington, Seattle, Washington, USA shows that Central injection of FGF1 induces sustained…

read more
Start Typing